StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2279.HK$2.09+0.48%
Fair $2.09+0.0%

2279.HK

Yonghe Medical Group Co., Ltd.

Healthcare / Medical Care FacilitiesHKSE

$2.09

+0.01 (+0.48%)

Fairly Valued+0.0%Fair Value $2.09Fund rank 29/100 · Data gapFallback financials|
SA 56/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $174.9M · quality 51.3/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 27/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

56/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 2279.HKLocal privado en este navegador · Yonghe Medical Group Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.0B

P/E

12.3x

↓

EV/EBITDA

2.2x

↓

ROE

9.4%

↑

Gross Margin

66.0%

↑

Debt/Equity

0.62

↑
52-Week Range$2
$1$4

TradingView lightweight chart

2279.HK price, volumen y niveles de valoración

Último $2.090Periodo -87.4%
Fair value: $2.090

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+8.6%

FCF CAGR

—

FCF margin

26.4%

FCF / Net income

6.47x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.81B · net income $73.7M · FCF $476.6M

2022-FY → 2025-FY

Gross margin

66.0%+4.3% pts

Operating margin

7.3%+18.6% pts

Net margin

4.1%+10.2% pts

FCF margin

26.4%+51.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.81B$1.81B$1.80B$1.78B$1.41B
Net Income$73.7M$73.7M$-226.3M$-546.4M$-85.9M
EBITDA$372.2M$372.2M$101.1M$-196.2M$166.4M
EPS0.150.15-0.45-1.08-0.16
Gross Margin66.0%66.0%60.1%56.1%61.8%
Operating Margin7.3%7.3%-6.9%-25.4%-11.4%
Net Margin4.1%4.1%-12.5%-30.7%-6.1%
Balance Sheet
Debt/Equity0.620.620.931.160.65
Current Ratio1.551.55———
Cash Flow
Free Cash Flow$476.6M$476.6M$174.9M$-188.5M$-352.1M
Returns
ROE9.4%9.4%-31.7%-58.0%-5.4%
Valuation
P/E12.2912.29———
EV/EBITDA2.232.236.03—37.03
P/B1.331.330.601.213.59
Growth & Yield
Revenue Growth0.2%0.2%1.5%25.8%—
EPS Growth133.3%133.3%58.3%-575.0%—
Dividend Yield4.1%4.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

7.3%

razonable

EPS terminal req.

$0.19

Spread vs growth

126.0%

5Y implied EPS CAGR

8.4%

razonable

EPS terminal req.

$0.22

Spread vs growth

124.9%

10Y implied EPS CAGR

9.2%

razonable

EPS terminal req.

$0.36

Spread vs growth

124.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +92.4%

Total return

+92.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.45 → 0.15

Residual

+88.3%

EPS growthn/d
Multiple reratingn/d
Dividend+4.1%
Residual / FX / buybacks / cross-term+88.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.